We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+12.11%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$177M
AUM Growth
+$177M
Cap. Flow
+$20.1M
Cap. Flow %
11.35%
Top 10 Hldgs %
37.39%
Holding
117
New
21
Increased
27
Reduced
33
Closed
35

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$3.68M
2
FULC icon
Fulcrum Therapeutics
FULC
+$3.52M
3
CERS icon
Cerus
CERS
+$3.5M
4
ARVN icon
Arvinas
ARVN
+$3.29M
5
NXTC icon
NextCure
NXTC
+$3.18M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$5.49M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$2.79M
3
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$2.54M
4
RNLX
Renalytix plc American Depositary Shares
RNLX
+$2.3M
5
CRIS icon
Curis
CRIS
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 89.56%
2 Financials 5.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSAC
51
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$1.07M 0.61%
110,040
-263,235
-71% -$2.54M
KURA icon
52
Kura Oncology
KURA
$793M
$1.06M 0.6%
56,614
-25,959
-31% -$489K
AKLI
53
DELISTED
Akili Inc
AKLI
$1.05M 0.6%
106,000
-144,000
-58% -$1.42M
DNAB
54
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$1.05M 0.59%
106,000
-144,000
-58% -$1.42M
DNAD
55
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$1.04M 0.59%
106,000
-144,000
-58% -$1.42M
CRNX icon
56
Crinetics Pharmaceuticals
CRNX
$8.88B
$1.04M 0.59%
+49,382
New +$1.03M
PROK icon
57
ProKidney
PROK
$316M
$1.04M 0.59%
106,000
-144,000
-58% -$1.42M
LONA
58
LeonaBio Inc
LONA
$66.1M
$998K 0.56%
10,639
-1,159
-10% -$118K
MREO
59
Mereo BioPharma
MREO
$48.9M
$885K 0.5%
365,661
-40,210
-10% -$106K
RNLX
60
DELISTED
Renalytix plc American Depositary Shares
RNLX
$742K 0.42%
37,000
-89,145
-71% -$2.3M
NTLA icon
61
Intellia Therapeutics
NTLA
$1.51B
$664K 0.38%
+4,950
New +$749K
EVGN icon
62
Evogene
EVGN
$5.83M
$656K 0.37%
24,833
-11,292
-31% -$329K
DRNA
63
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$626K 0.35%
31,040
-198,852
-86% -$5.49M
PNT
64
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$552K 0.31%
+71,729
New +$654K
HELP
65
Cybin Inc
HELP
$490M
$549K 0.31%
+6,579
New +$576K
GH icon
66
Guardant Health
GH
$19.1B
$527K 0.3%
4,218
-455
-10% -$54.1K
CABA icon
67
Cabaletta Bio
CABA
$427M
$511K 0.29%
+42,022
New +$388K
ISEE
68
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$487K 0.28%
+30,000
New +$326K
CRIS icon
69
Curis
CRIS
$9.71M
$486K 0.27%
155
-494
-76% -$1.54M
AYLA
70
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$464K 0.26%
40,956
+17,592
+75% +$211K
EVLO
71
PUT
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$434K 0.25%
+3,085
New +$611K
CALA
72
DELISTED
Calithera Biosciences, Inc
CALA
$406K 0.23%
9,312
+7,743
+493% +$334K
KROS icon
73
Keros Therapeutics
KROS
$197M
$396K 0.22%
+10,000
New +$356K
SURF
74
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$379K 0.21%
50,000
-44,539
-47% -$285K
RAPT
75
DELISTED
RAPT Therapeutics
RAPT
$366K 0.21%
1,475
-4,424
-75% -$1.17M
1 2
3
4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Silverarc Capital Management held 117 positions worth $177M, up 78,789% from $224K the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Silverarc Capital Management deployed $20.1M of net new capital in Q3 2021, opening 21 new positions and adding to 27 existing holdings. Its largest new stake was Fulcrum Therapeutics: 185,691 shares worth $5.24M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $5.49M trimmed.

  • Silverarc Capital Management's largest Q3 2021 buy was Fulcrum Therapeutics: 185,691 shares worth $5.24M.
  • Silverarc Capital Management added most to Cogent Biosciences in Q3 2021, an estimated $3.68M increase.
  • Silverarc Capital Management's biggest Q3 2021 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $5.49M.
  • Silverarc Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $12.8K.
  • Silverarc Capital Management's ten largest holdings make up 37% of its $177M portfolio in Q3 2021.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q3 2021.
  • Silverarc Capital Management's portfolio value rose 78,789% quarter-over-quarter to $177M.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.